Filing Flows › Kyntra Bio (KYNB) › Q1 2026 › vs Q1 2025
Kyntra Bio (KYNB) Q1 2026 vs Q1 2025 (year over year)
Kyntra Bio's revenue rose $999K (+36%) from $2.7M in Q1 2025 to $3.7M in Q1 2026. The biggest changes: Drug Product Revenue +$897K (+35%); Development and Other Revenue +$102K (+71%).
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Drug Product Revenue | $3.5M | $2.6M | $897K | +35% |
| Development and Other Revenue | $246K | $144K | $102K | +71% |
| Revenue | $3.7M | $2.7M | $999K | +36% |
| Net loss | $15.2M | −$4.6M | $19.8M | — |
| Costs & expenses | $18.9M | $22.3M | −$3.4M | -15% |
| Operating costs | $17.6M | $17.7M | −$103K | -0.6% |
| Interest & other, net | $1.4M | −$19.6M | $20.9M | — |
| Cost of revenue | $4.1M | $252K | $3.9M | 16× |
| Research & development | $7.6M | $9.2M | −$1.6M | -18% |
| SG&A | $5.9M | $8.1M | −$2.2M | -28% |
| Operating cash sources | $15.2M | −$5.0M | $20.2M | — |
| Share-based compensation | $1.2M | $2.9M | −$1.7M | -60% |
| Working capital & other | $160K | −$5.1M | $5.2M | — |
| Cash used in operations | $13.9M | −$2.7M | $16.6M | — |
| Net loss absorbed | $15.2M | −$4.6M | $19.8M | — |
Questions
How much did Kyntra Bio's revenue grow year over year in Q1 2026?
Kyntra Bio's revenue rose $999K (+36%) from $2.7M in Q1 2025 to $3.7M in Q1 2026.
What drove Kyntra Bio's revenue change in Q1 2026?
Drug Product Revenue +$897K (+35%); Development and Other Revenue +$102K (+71%).